Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QVM149 versus salmeterol/fluticasone + tiotropium in uncontrolled severe asthma
MOH_2018-03-20_002025Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of indacaterol acetate + glycopyrronium bromide + mometasone furoate, salmeterol, fluticasone propionate and tiotropium in asthma and severe asthma (3 arms), sponsored by Novartis. Primary endpoint: Asthma symptom and breathing relief comparison. Started Mar 2018; status: completed.
02
Drugs
indacaterol acetate + glycopyrronium bromide + mometasone furoatesalmeterolfluticasone propionatetiotropium
03
Conditions
asthmasevere asthma
Beyond the preview
Go deeper on MOH_2018-03-20_002025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-03-20_002025.